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Objectives: To present sales ﬁgures of antifungal drugs for treatment of genital Candida infections in females,
which had been purchased in the Swedish county of Ska ˚ne (with approximately 1.2 million inhabitants) during
the 1990s. To study the relative proportions of the drugs sold by prescription and as over-the-counter (OTC)
products.
Methods: Sales ﬁgures of antifungal drugs for therapy of vulvovaginal candidiasis (VVC) and such recurrent
infections (RVVC), for the years 1990–99, were collected from the ‘ACS’ database of the National Corporation
of Swedish Pharmacies.
Results: The study showed an increase in sales of the type of drugs studied from 45000 packages in 1990 until
mid-93/94, when approximately 70000 packages were sold (mainly azoles for topical use and ﬂuconazole for
oral intake). Thereafter there was a decrease until the end of November 1999, when 54000 packages were
purchased. Of the total sales, 93% were OTC products. Sales of clotrimazole and econazole (for vaginal
installation) in 1993–1994 were equal to 85–90 packages/1000 women in the age group 15–45 years. Extremely
high sales volumes of ﬂuconazole and itraconazole, for one single year each, could be explained by marketing-
related activities directed to the medical community.
Conclusions: As many women with RVVC are not cured by iatrogenic initiatives and women consider
themselves able to diagnose episodes of genital Candida infection, affected women generally turn to self-
medication with antifungal OTC products. This stresses the role of pharmacy counseling. Short-term marked
alterations in sales volumes may be due to marketing factors rather than changes in the epidemiology of genital
Candida infections.
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It is estimated that approximately three-quarters
of all women will suffer from at least one episode
of vulvovaginal candidiasis (VVC) during their
lifetime and that about 5% will experience
recurrent episodes (RVVC)
1,2. However, the
proportion of false diagnoses of attacks of RVVC
is high
3. Not only the women themselves with an
assumed history of RVVC and with current
symptoms generally associated with VVC, but
also health-care providers overdiagnose the pre-
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DOI: 10.1080/10647440400003873sence of yeast fungi in the genital tract in up to
half of all such instances
4.
Women with RVVC may have consulted one
or more physician(s) several times before con-
tinuing self-treatment with antifungal drugs
available as over-the-counter (OTC) products,
or they even start such treatment directly after
counseling with a pharmacist
5,6. Thus, hospital
and outpatient clinic records can hardly serve as
reliable sources of information in attempts to
understand the epidemiology of genital Candida
infections.
The majority of strains causing both VVC and
RVVC belong to C. albicans. A switch of ﬂora to
non-albicans strains – with a natural low suscept-
ibility to azole drugs – may, however, occur in
RVVC cases, which may result in therapeutic
problems
7,8.
All pharmacies in Sweden are state-owned and
the only ones that are allowed to sell medical
drugs in the country, including antifungal OTC
products. The sales of all medical drugs are
registered in a database
9, which offers a unique
opportunity to study usage not only of prescribed
drugs, but also of OTC products.
The present study was undertaken to analyze
the sales ﬁgures of antifungal drugs, both
prescriptions and OTC products, aimed at the
therapy of VVC/RVVC, which had been
purchased at pharmacies in Ska ˚ne county, Swe-
den, during the 1990s.
MATERIAL AND METHODS
Study population
The female population of Ska ˚ne county during
the 1990s consisted of approximately 660000
individuals.
Antifungal drugs available during the study
period
The drugs for therapy of VVC/RVVC that were
available in Sweden during the 1990s, as well as
their trade names, galenic forms, available package
sizes, year of registration in Sweden and from
which year they were available as OTC products,
are shown in Table 1.
Database and analyses performed
Data on drugs sold more or less exclusively for
therapy of genital Candida infections in females
were studied. The data were derived from
Apoteket AB’s database ‘ACS’ for the period
January 1990 to the end of November 1999
9.A t
the start of collection of the ‘ACS’ data in 1974, it
surveyed one in 288 prescriptions. Later, this was
the case for one in every 25 samples. From 1997
onwards, the database has registered all dispensed
prescriptions. The data recorded for prescriptions
are: trade name, total cost and quantity of the
drugs purchased, and sex and year of birth of the
customer. Also, the sum paid by the customer, if
any (related to subsidies), is registered. All OTC
sales are also registered, but could not be analyzed
as to sex and age of consumer, as customers are
not requested to supply any personal information.
We analyzed all packages of antifungal drugs
aimed for vaginal installation, i.e. clotrimazole
(Canesten
1), econazole (Pevaryl
1) and micona-
zole (Daktar
1). Furthermore, we analyzed ﬁgures
for one capsule of 150 mg ﬂuconazole (Diﬂu-
can
1) and four capsules of 100 mg itraconazole
(Sporanox
1) (which package sizes are more or
less only used for therapy of VVC/RVVC). We
chose to analyze the number of packages sold,
instead of Deﬁned Daily Dose, which we found
more relevant for sales of drugs particularly used
to treat VVC and RVVC. For ﬂuconazole and
itraconazole, we investigated only the sales ﬁgures
for the above-mentioned package sizes, because
they are especially aimed for these two indica-
tions.
The number of pharmacies in Ska ˚ne remained
fairly constant, at around 100, during the study
period. Pharmacies in the county had shelves
displaying OTC medications for self-selection of
available products by the customers themselves.
RESULTS
Figure 1 shows the total consumption of vaginal
preparations of econazole, miconazole and clo-
trimazole during the period January 1990–
November 1999. Usage of these drugs increased
from approximately 45000 packages in 1990 to
approximately 70000 in 1994, an increase of 38%.
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mately 53000 packages sold in 1999, i.e. a 26%
decrease. Econazole was the drug purchased
predominantly, holding two-thirds of the market.
Both clotrimazole and econazole, applicable
either as creams or vaginal suppositories, could be
bought in Sweden as OTC products since 1994
and 1993, respectively. The sale of intravaginal
preparations of these drugs in Ska ˚ne county
during 1993–1994 was equal to 85–90 units/
1000 women in the age group 15–60 years.
The sales volumes of packages of 150 mg
ﬂuconazole and packages with four capsules of
100 mg itraconazole, purchased between 1990
and 1999, are shown in Figure 2. These packages,
both aimed for per os therapy of VVC and RVVC,
held more than 90% of the market. Diﬂucan was
introduced onto the market in 1989 and Spor-
anox in 1993. Figure 3 shows the sales of one-
capsule packages of 150 mg ﬂuconazole to
different age groups in the county during the
1990s. Peak sales occurred in 1993. The number
of packages sold per 1000 inhabitants was roughly
the same over the study period, ranging from 5 to
35 packages, depending on consumer age group
(with the exception of the year 1993). The usage
of packages containing four capsules of 100 mg
itraconazole according to age group is illustrated
in Figure 4. As evident from the ﬁgure, the sales
volume for 1995 differed markedly from the other
years studied.
DISCUSSION
To study the epidemiology of VVC and RVVC
in an area by means other than analyzing the sales
ﬁgures for drugs used to treat these infections is
impossible. This is because, as evident from our
study, the vast majority of episodes of these
conditions are treated by the affected women
themselves, by the use of OTC products. Thus,
93% of all drugs used for therapy of these
conditions in the county, were sold over the
counter.
The marked increase in sales of ﬂuconazole in
1993 is most likely explained by a marketing
campaign by the product manufacturer in that
particular year, and is unlikely to reﬂect any
change in the epidemiology of VVC and RVVC.
The extreme sales volume in 1995 of packages
Table 1 Drugs available for therapy of vaginal Candida infections in Sweden during the 1990s
Substance
name Preparation Galenic form Package size
Registered
in
OTC
since
Clotrimazole Canesten
1 Vaginal cream, 1% 6 pack 1980 1994
Clotrimazole Canesten
1 Vaginal cream, 10% one 1986 1994
Clotrimazole Canesten
1 Pessaries, 100 mg 6 pack 1975 1994
Clotrimazole Canesten
1 Pessaries, 200 mg 3 pack 1982 1994
Clotrimazole Canesten
1 Pessaries, 500 mg one 1983 1994
Clotrimazole Canesten
1 Combination pack 36200 mg pessaries+1% cream 1995 1995
Clotrimazole Canesten
1 Combination pack 16500 mg pessary+1% cream 1995 1995
Econazole Pevaryl
1 Pessaries, 50 mg 15 pack 1977 Rx only
Econazole Pevaryl
1 Pessaries, 150 mg 3 pack 1979 1993
Econazole Pevaryl
1 Vaginal cream, 1% 78 g 1977 1993
Econazole Pevaryl
1 Combination pack 36150 mg pessaries+1% cream 1994 1994
Econazole Pevaryl Depot
1 Pessaries, 150 mg one 1985 1994
Econazole Pevaryl Depot
1 Combination pack 16150 mg pessary (Depot)+1%
cream
1994 1994
Miconazole Daktar
1 Vaginal cream, 2% 50 g 1974 Rx only
Miconazole Daktar
1 Pessaries, 400 mg 3 pack 1981 Rx only
Fluconazole Diﬂucan
1 Capsules, 150 mg one 1989 Rx only
Itraconazole Sporanox
1 Capsules, 100 mg 4 pack 1994 Rx only
OTC, over-the-counter; Rx, prescription
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Figure 1 Total usage of vaginal preparations of econazole (Pevaryl
1), miconazole (Daktar
1) and clotrimazole
(Canesten
1), sold either by prescription or as over-the-counter products in Ska ˚ne county, Sweden, during the 1990s
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Figure 2 Number of prescriptions of 150 mg (single-dose) ﬂuconazole (Diﬂucan
1) and of four capsules of 100 mg
itraconazole (Sporanox
1), with genital Candida infection in females as the sole indication, sold in Ska ˚ne county,
Sweden, during the 1990s
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Figure 3 Number of prescriptions of one capsule of 150 mg ﬂuconazole (Diﬂucan
1) sold per age group in Ska ˚ne
county, Sweden, during the 1990s
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Figure 4 Number of prescriptions of four capsules of 100 mg itraconazole (Sporanox
1) sold per age group in Ska ˚ne
county, Sweden, during the 1990s
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(aimed for VVC/RVVC) is explained by the fact
that only such packages were available for a new
indication for the drug, namely for invasive
(pulmonary) aspergillosis, which required such
high dosages. Furthermore, our study shows that
usage of four-capsule packages of itraconazole was
mainly restricted to a small number of patients,
i.e. in the age group 60–64 years. These examples
illustrate that an unexpected rise in sales of an
antifungal drug may be due to factors related to
activities of the pharmaceutical drug industry,
rather than to any change in the epidemiology of
fungal infections.
A multifactorial explanation is likely for the
changes over time seen in Ska ˚ne county in the
sales of antifungal drugs for therapy of VVC/
RVVC. It could involve demographic factors,
e.g. alterations in the number of women living in
the study area, particularly in age groups most
susceptible to VVC and RVVC. However, there
were only very small changes in the number of
female inhabitants and their age distribution in the
county during the 1990s.
Increased use of contraceptives, particularly
of oral contraceptive pills containing gestagens
and of hormone-releasing intrauterine devices
(IUDs), could have contributed to an increased
rate of VVC and RVVC and thereby to the
changed sales volumes observed, as sex hormones
stimulate germ tube formation (GTF) of Candida
cells
10 and extracellular matrix proteins may
increase the chance of colonization of the
vagina
11. GTF is a prerequisite for tissue invasion
of yeast cells. The sales of oral contraceptives in
Ska ˚ne increased by 20% during the 1990s, a trend
that continued also at the latter part of the decade.
Thus, these sales did not mirror those of the
antifungal drugs. On the other hand, the purchase
of hormone-releasing IUDs followed the increas-
ing and decreasing trends in the sales volumes of
the antifungal drugs over the decade. However,
the number of IUDs sold ranged from only 2250
to 4500 per annum, with a sales peak of 14000
devices for the 2-year period 1994–95.
Any increase in the prescription of hormone
replacement therapy to postmenopausal women,
which is known to enhance the rate of genital
Candida infections
12, could also have resulted in a
greater usage of antifungal drugs. However, such
prescriptions to postmenopausal women did not
increase during the study period, although usage
of high-dose estrogen preparations tripled during
the 1990s. However, estrogen – in contrast to
progesterone – may not inﬂuence GTF
10.
The number of prescriptions of antifungal
drugs used mainly for therapy of VVC/RVVC
among the populations in the different munici-
palities in Ska ˚ne county showed great variation
and was related to the density of the female
population in the municipality, even after adjust-
ing for the age of the inhabitants
13.I n
comparison, the sales of all medical drugs to the
same cohort of women in the different munici-
palities did not show any such trend. That is,
usage of medical drugs in general was not higher
in the mainly urban than in the mainly rural areas
in the county, which was the case for the
antifungals studied. The health-seeking behavior
of urban and rural populations might differ,
inhabitants in the former areas may more often
consult for problems considered less serious, like
genital Candida infections.
In Sweden, when a woman at telephone
consultation reports symptoms suggestive of a
genital Candida infection, a common recom-
mendation is to buy an antifungal OTC product
rather than to consult a physician. In the case
that a woman attends a consultation, it will often
occur with the involvement of a midwife (who
is allowed to deal with these conditions and to
prescribe drugs for local therapy of VVC). In the
latter case, the national health insurance may pay
the total cost of the drug or for some of it.
Obviously, pharmacy counseling plays an im-
portant role in the management of VVC/
RVVC.
Wide use of antifungal drugs has been discussed
as one factor promoting the development of
resistance in Candida
14,15, which may be an
argument to reduce the present uncontrolled,
liberal access to antifungal drugs as OTC
products. On the other hand, OTC preparations
for self-treatment of VVC and RVVC may, if
used properly, provide patients with a faster cure
at a lower cost
16,17. However, as mentioned,
accurate diagnosis of VVC/RVVC by the patient
herself, a physician or a counseling pharmacist, on
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problem. There seems to be a need for contin-
uous postgraduate education of pharmacists and
other pharmacy employees on infectious condi-
tions affecting the genital tract
18.
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